Clinical trials: Attention Deficit Disorders With Hyperactivity
- Condition Attention Deficit Disorders With Hyperactivity
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Disorder With Hyperactivity (ADHD)
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.
- Trial name
- NCT07755410
- Testing
- ALKS 7290
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Alkermes, Inc.
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01199315
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Attention Deficit Disorder With Hyperactivity
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study aims to assess the effectiveness of atomoxetine on psychosocial functioning and emotional well being of children and adolescents with ADHD and to evaluate whether and in what measure the presence of comorbid conditions…
- Trial name
- NCT00320528
- Testing
- atomoxetine
- Where
- 20 sites in Italy
- Volunteers
- 269 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.
- Trial name
- NCT02811211
- Where
- United States
- Volunteers
- 1,894 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder
- Trial name
- NCT00191880
- Testing
- atomoxetine
- Where
- 8 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
ADHD, Narcolepsy
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
This is a randomized, double-blind, double-dummy, placebo- and active-controlled 4 period, 4 way crossover study to assess the intranasal abuse potential of manipulated ADAIR formulation in nondependent, recreational stimulant…
- Trial name
- SEAL (NCT04647903)
- Testing
- ADAIR 10 mg IR tablets, d-amphetamine sulfate
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vallon Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00686933
- Testing
- ABT-089
- Where
- 12 sites in United States
- Volunteers
- 117 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention Deficit Hyperactivity Disorder
CX717 in the Treatment of Adult ADHD
A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder
- Trial name
- NCT03375021
- Testing
- CX717 200 mg, CX717 800 mg
- Volunteers
- 68 people
- Sponsor
- RespireRx
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or…
- Trial name
- NCT03605836
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.
- Trial name
- NCT00190931
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Adult ADHD
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
- Trial name
- NCT01012375
- Testing
- AZD1446
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder (ADHD)
Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55…
- Trial name
- NCT01328756
- Testing
- Lisdexamfetamine dimesylate
- Where
- 35 sites in Belgium, Germany and 8 more
- Volunteers
- 314 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD
The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.
- Trial name
- NCT00191698
- Testing
- atomoxetine hydrochloride
- Where
- 16 sites in Australia, Belgium and 6 more
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Short Structured Psychological Intervention for Adults With ADHD - a Randomized Controlled Trial
The purpose of this study is to evaluate the effects of a novel psychological intervention for adult ADHD through a randomized controlled trial.
- Trial name
- NCT04439422
- Testing
- Short ADHD Intervention, Self-help material with limited therapist support
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Cereb AB
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
Attention Deficit Hyperactivity Disorder
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine extended-release oral suspension, CII) for the treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12…
- Trial name
- NCT03088267
- Testing
- amphetamine extended-release oral suspension, 2.5 mg/mL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tris Pharma, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
- Trial name
- NCT02578030
- Testing
- SHP465 12.5mg, SHP465 25mg
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.
- Trial name
- NCT00562055
- Testing
- Atomoxetine, PNU-165442G; [S,S]-reboxetine
- Sponsor
- Pfizer
Attention Deficit Disorder With Hyperactivity
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
- Trial name
- NCT00174226
- Testing
- Atomoxetine, Buspirone
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Pfizer